RxDoctor Payments Data

Samantha Schneider Johnson, DO

Ophthalmology · Corona, CANPI 1457840035

Payments from drug & device makers

$671in general payments, 2019–2025

Across 17 payments — averaging $39.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$385
  • Amgen$118
  • Rxsight Inc$105
  • Bausch & Lomb Americas Inc.$39
  • Harrow Eye, LLC$23

What the payments were for

  • Speaking & faculty fees$264%
  • Food & beverage$64596%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon8$385
Amgen1$118
Rxsight Inc5$105
Bausch & Lomb Americas Inc.2$39
Harrow Eye, LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$671 in reported general payments places this provider in the 35th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$163,581
Medicare patients
425
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine38$24,871
Cyclosporine57$22,758
LumiganBimatoprost32$16,453
Prednisolone Acetate431$11,137
MoxifloxacinMoxifloxacin Hcl363$8,323
Travatan ZTravoprost13$7,496
Ketorolac Tromethamine384$5,561
Brimonidine Tartrate79$4,600
Latanoprost380$4,303
RhopressaNetarsudil Mesylate14$4,143
Alphagan PBrimonidine Tartrate12$3,451
SimbrinzaBrinzolamide/Brimonidine Tart16$3,310
Fluorometholone40$2,525
Travoprost12$1,541
Timolol Maleate116$1,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$385$3,31016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →